We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Protein Biomarker Blood Test Accurately Detects Alzheimer’s Disease

By LabMedica International staff writers
Posted on 07 Jul 2021
Print article
Image: The proximity extension assay identified 19 plasma hub proteins (indicated as yellow dots in the figure) in AD patients, which were irregular compared to healthy people (Photo courtesy of Hong Kong University of Science and Technology)
Image: The proximity extension assay identified 19 plasma hub proteins (indicated as yellow dots in the figure) in AD patients, which were irregular compared to healthy people (Photo courtesy of Hong Kong University of Science and Technology)
A 19-protein biomarker panel distinguished Alzheimer’s disease (AD) patients from healthy individuals with greater than 96% accuracy and differentiated among the early, intermediate, and late stages of AD while monitoring the progression of the disease.

To capitalize on results obtained by studies showing the potential of blood proteins as candidate biomarkers for AD, investigators at Hong Kong University of Science and Technology (China) and their colleagues at University College London (United Kingdom) systematically profiled the plasma proteome to identify novel AD blood biomarkers and develop a high-performance, blood-based test for AD.

To do this, they used a proximity extension assay technique to quantify 1160 plasma proteins in samples obtained from a Hong Kong Chinese cohort. Proximity extension assay (PEA) is a direct one-step protein quantification method using a pair of DNA oligonucleotides linked to antibodies against the target molecule. It requires polyclonal or two monoclonal antibodies that bind to target epitopes close enough to form a DNA duplex which is quantified by real-time PCR.

The results of the PEA analysis identified 429 proteins that were dysregulated in the plasma of AD patients. The investigators selected 19 "hub proteins" representative of the AD plasma protein profile, which were used to form the basis of a scoring system that accurately classified clinical AD (as characterized by the presence of amyloid, tau, phosphorylated tau, and neurodegeneration).

In addition to distinguishing AD patients from healthy individuals with more than 96% accuracy, the system could also differentiate among the early, intermediate, and late stages of AD and be used to monitor the progression of the disease over time.

"With the advancement of ultrasensitive blood-based protein detection technology, we have developed a simple, noninvasive, and accurate diagnostic solution for AD, which will greatly facilitate population-scale screening and staging of the disease," said senior author Dr. Nancy Ip, professor of life science at Hong Kong University of Science and Technology.

The plasma protein screening method for detection of Alzheimer’s disease was described in the May 25, 2021, online edition of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Related Links:
Hong Kong University of Science and Technology
University College London



Platinum Supplier
Hormonal Test
Endocrine Array
New
HBV Test
ELISA HBV Test Kit
New
POC Pathogen Detection & Gene Expression System
Sal6830 Mobile Workstation
New
Dual-Channel Optical Coagulation Analyzer
Sensa2

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.